“Bendamustine Is a Hybrid Antimetabolite and Alkylating Agent Offering New Therapeutic Options for the Treatment of Non-Hodgkin Lymphomas”. Hematology Meeting Reports, vol. 2, no. 5, June 2009, https://doi.org/10.4081/hmr.v2i5.749.